Fortis, TotipotentRX collaborate

Wednesday, March 16, 2011 12:48 PM

New Delhi, India-based Fortis Healthcare is collaborating with U.S.-based TotipotentRX Cell Therapy to set up stem cell therapy centers across its hospitals, according to BIO SmartBrief.

The centers will offer cellular therapies and will undertake stem cell clinical research procedures relating to diabetes, cancer, cardiovascular disease and neurological ischemia, Fortis Healthcare said.

"This allows Fortis to partner with the finest in the field of stem cell therapy and lead the way in this specialized new treatment modality, acknowledged to be at the cutting edge of modern medicine," said Shivinder Mohan Singh, Fortis Healthcare’s managing director.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs